Biomedical subjects

Jacqueline Jozefonvicz

Publications and source records attributed to Jacqueline Jozefonvicz.

6 recordsLinked to original sources

PubMed2006

Dextran derivatives modulate collagen matrix organization in dermal equivalent.

Dextran derivatives can protect heparin binding growth factor implied in wound healing, such as transforming growth factor-beta1 (TGF-beta1) and fibroblast growth factor-2 (FGF-2). The first aim of this study was to investigate the effect of these compounds on human dermal fibroblasts in culture with or without TGF-beta1. Several dextran derivatives obtained by substitution of methylcarboxylate (MC), benzylamide (B) and sulphate (Su) groups were used to determine the effects of each compound on fibroblast growth in vitro. The data indicate that sulphate groups are essential to act on the fibroblast proliferation. The dextran derivative LS21 DMCBSu has been chosen to investigate its effect on dermal wound healing process. Fibroblasts cultured in collagenous matrices named dermal equivalent were treated with the bioactive polymer alone or associated to TGF-beta1 or FGF-2. Cross-sections of dermal equivalent observed by histology or immunohistochemistry, demonstrated that the bioactive polymer accelerates the collagen matrices organization and stimulates the human type-III collagen expression. This bioactive polymer induces apoptosis of myofibroblast, property which may be beneficial in treatment of hypertrophic scar. Culture media analyzed by zymography and Western blot showed that this polymer significantly increases the secretion of zymogen and active form of matrix metalloproteinase-2 (MMP-2), involved in granulation tissue formation. These data suggest that this bioactive polymer has properties which may be beneficial in the treatment of wound healing.

Actins↗

PubMed2004

Anti-prothrombin antibodies as a potential risk factor of recurrent venous thromboembolism.

The role of antiprothrombin (aPT) antibodies in the development of venous thromboembolism (VTE) is still uncertain. The aim of this study was to evaluate the potential role of aPT antibodies in the development of recurrent thromboembolism. Out of 236 consecutive symptomatic patients with an episode of acute VTE, antiphospholipid antibodies were found in 85 (36.0%), of whom 24 were carriers of aPT antibodies (10.2% of the entire cohort). A history of previous thromboembolism was identified in 56 patients (23.7%). The prevalence of previous thromboembolism was significantly higher in carriers than in non-carriers of antiphospholipid antibodies (OR=2.4; 95% CI, 1.3 to 4.4). Of the 24 patients with aPT antibodies, 12 had a history of previous thromboembolism. In a multivariate logistic regression analysis, in which the other categories of antiphospholipid antibodies were taken into account, as well as the patient's age, sex, and the modality of clinical presentation, it was found that the presence of aPT antibodies was significantly associated with the prevalence of prior thromboembolism (OR=3.3; 95% CI, 1.3 to 8.6). Since aPT antibodies are more commonly identifiable in patients with multiple thrombotic episodes, they are a likely risk factor for recurrent thromboembolism.

Adult↗

PubMed2004

Effect of a dextran derivative associated with TGF-beta1 or FGF-2 on dermal fibroblast behaviour in dermal equivalents.

Dextran derivatives that mimic the action of heparin have been shown to protect heparin-binding growth factors, such as Transforming Growth Factor-beta1 (TGF-beta1) and Fibroblast Growth Factor-2 (FGF-2). The aim of this study was to investigate the effect of LS21 DMCBSu, a dextran derivative which contains methylcarboxylate, benzylamide and sulfate groups, both by itself and when combined with TGF-beta1 and FGF-2, on the behaviour of fibroblasts. Two systems were assessed: a monolayer culture and three-dimensional collagenous matrices (dermal equivalent). Polymeric biomaterial LS21 DMCBSu and LS21 DMCBSu associated with either TGF-beta1 or FGF-2, were added to the monolayer culture on day 3. After 7 days of culture the number of cells was determined. Two treatments were carried out on the dermal equivalents: 9 days of treatment from day 0 to day 9 of culture and 9 days of treatment from day 21 to day 30 of culture for the premature and the mature dermal equivalents respectively. In the monolayer culture, the bioactive polymer produced a slight increase in fibroblast growth (10% with 10 microg/ml of LS21 DMCBSu) and promoted the stimulating effect of the growth factors on cell growth. In the premature dermal equivalents growth was stimulated by 20% when 10 microg/ml LS21 DMCBSu was added. The dextran derivative mixed with TGF-beta1 slightly inhibited the growth effect of the growth factor in the dermal equivalents. The functionalized dextran with FGF-2 enhanced the stimulating effect of the growth factor in the premature dermal equivalent. A significant increase in cell growth was observed with the fibroblasts treated with the FGF-2 LS21 DMCBSu mixture and FGF-2 (51% and 40%, respectively). However, none of the described treatments affected the cell growth in the mature dermal equivalent. Furthermore, the dextran derivative had no effect on dermal contraction under these experimental conditions (3D culture).

Cell Differentiation↗

PubMed2002

A new vascular polyester prosthesis impregnated with cross-linked dextran.

It is essential that a synthetic vascular graft is preclotting prior to implantation in order to prevent blood leaking through the graft wall. We have impregnated a knitted polyester prosthesis with cross-linked dextran. The aim of this study was to develop a process for obtaining an impervious prosthesis and to compare the characteristics of this dextran-impregnated graft with those of a commercially available collagen-impregnated graft. This new vascular prosthesis was coated with dextran; sodium trimetaphosphate was utilized as the cross-linking agent. In an attempt to determine the optimal conditions for impregnation, the dynamic viscosity of the dextran solution was measured during the cross-linking reaction. The results suggest that the dynamic viscosity is correlated with the concentrations of dextran, sodium hydroxide, and sodium trimetaphosphate. The effect of temperature on the dynamic viscosity was also investigated. The water permeability, the coating weight, and the structure of the dextran-impregnated graft were compared with those of a collagen-impregnated prosthesis. The water permeability of the vascular grafts was reduced by dextran impregnation, from 1010 ml/min per cm2 for the control to 0.04 ml/min per cm2 under standard testing conditions. The dextran coating is capable of rendering the graft impervious to water. The coating weight of the graft treated with dextran was approximately the same as the weight of the collagen-impregnated graft. Finally, the morphology of the prosthetic wall was analyzed using scanning electron microscopy. The promotion of endothelial cell recovery was only observed for the polyester grafts treated with dextran or collagen.

Blood Vessel Prosthesis↗

PubMedDate not supplied

Anti-proliferative and antitumoral activities of a functionalized dextran (CMDBJ) on the 1205 L-U human tumor melanoma cells.

Carboxy methyl dextran benzylamide jorge (CMDBJ) is a derivatized dextran prepared from native dextran after random carboxymethylation of hydroxyl groups on D-glucose units (CM) and consecutive conversion of some carboxylate groups to benzylamide structures (B). This polymer exhibits an inhibitory action upon the proliferation of 1205 L-U human melanoma cells. At low concentrations, this compound exerts a cytostatic effect whereas, at higher concentrations, a cytotoxicity appears within 24 hours of treatment. The 1205 L-U cell line forms subcutaneous angiogenic tumors in athymic mice and, after several weeks, spontaneously forms micrometastasis in the lungs. We demonstrated that the CMDBJ treatment of animals not only reduces the rapid growth of primary tumors but also induces tumor regression and tumor necrosis. Moreover, CMDBJ treatment blocks the appearance of lung metastasis. Pleiotrophin (PTN), heparin-binding angiogenic growth factor, is secreted by 1205 L-U cells and breast tumor MDA-MB 231 cells. CMDBJ, as an inhibitor of heparin-binding growth factor activities, suppresses the mitogenic activity of conditioned media from 1205 L-U and MDA-MB 231 on endothelial HUVEC cells. We conclude that CMDBJ can inhibit the in vitro cell proliferation of 1205 L-U cells and 1205 L-U tumor development in athymic mice and that PTN secreted by these cells could be involved in this inhibition.

Animals↗

PubMedDate not supplied

In vitro effects of fucans on MDA-MB231 tumor cell adhesion and invasion.

Fucans are sulphated polysaccharides extracted from brown seaweed, which display a wide scale of activities including inhibition of tumour cell invasion. Like several sulphated polysaccharides, they have been shown to be potent inhibitors of experimental metastasis. However, their mechanism of action is not fully understood Using standard adhesion and chemoinvasion assays, we demonstrated that fucans can inhibit MDA-MB231 cell invasion through matrigel. This effect is correlated with a direct interaction of the fucans with laminin that leads to an inhibition of cell adhesion. It depends upon the sulphate content and the molecular weight of the fucans. Moreover, chromogenic assays allowed us to bring to the fore an increase of u-PA activity in the MDA-MB231 culture medium when tests were performed in the presence of fucans. Since tumour cell adhesion is a prerequisite step in the invasion process, our results suggest that the inhibitory effect of fucans on MDA-MB231 cell invasion is caused, at least in part, by the blockage of tumour cell adhesion to the extracellular matrix and by the increase of the proteolysis of the extracellular membrane.

Adenocarcinoma↗